Raymond James Downgrades Edwards Lifesciences (EW) to Market Perform
Get Alerts EW Hot Sheet
Rating Summary:
23 Buy, 18 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 10
Join SI Premium – FREE
Raymond James analyst Jayson Bedford downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform.
The analyst comments "We are downgrading our rating on EW to Market Perform (from Outperform), as we are less confident in the sustainable growth profile. EW’s revenue growth (10% 5-year, 13% 10-year avg.) has separated it from most of its peers and has long supported a premium valuation. Our concern, which has admittedly already weighed on the stock over the last few quarters is that recent TAVR trends continue (in the 7-8% range), which limits upside to estimates, and the multiple. With slowing TAVR growth, and increasing competition, we believe the narrative on the stock becomes more defensive, until U.S. TAVR growth sustainably accelerates or the rich pipeline gets closer to commercialization. While much of this thinking may already be reflected in the stock (and is a risk to our call), EW still trades at 33/29x 2023/24E non-GAAP EPS, which may deter new investment and makes it tougher to stay constructive without confidence that there is much upside to consensus estimates."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $82.12 yesterday.
You May Also Be Interested In
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
- Canaccord Genuity Downgrades Pivotree (PVT:CN) to Hold
- Barclays Downgrades NIBE Industrier AB (NIBEB:SW) (NDRBF) to Equalweight
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!